Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial

This study (n=211) reports treatment with benralizumab resulted in a 70mL improvement in prebronchodilator FEV1 after 12 weeks vs placebo (placebo group: 2246 mL at baseline vs 2261 mL at week 12; benralizumab group: 2248 mL vs 2310 mL) – statistical significance not achieved.

The researchers note that although the lung function improvement observed does not justify use of benralizumab in this population because it did not reach the minimum clinically important difference of 10%, further studies to assess this finding should be considered.

 

Separately, a study evaluating the oral glucocorticoid–sparing effect of benralizumab has been published in the New England Journal of Medicine.